Table 3.
Dosimetric data reported for the 16 patients with CT-planification and the 17 patients with MRI-planification
| Data | CT (n = 16) | MRI (n = 17) | |||||
|---|---|---|---|---|---|---|---|
| Median | Min-max | SD | Median | Min-max | SD | ||
| CTV | (cc) | 52.6 | 28.5-74.3 | 13.1 | – | – | – |
| D90CTV | (%) | 118.0 | 108.0-127.6 | 5 | – | – | – |
| (Gy) | 28.1 | 22.7-31.9 | 3 | – | – | – | |
| D90CTV EQD2αβ10 | (Gy) | 82.9 | 78.2-96.5 | 5.7 | – | – | – |
| HR-CTV | (cc) | – | – | – | 31.9 | 17.1-58.0 | 11.7 |
| D90HR-CTV | (%) | – | – | – | 122.4 | 107.9-135.9 | 7.2 |
| (Gy) | – | – | – | 25.7 | 22.7-28.5 | 1.5 | |
| EQD2αβ10 D90HR-CTV | (Gy) | – | – | – | 84.8 | 80.6-91.4 | 3.1 |
| IR-CTV | (cc) | – | – | – | 83.1 | 53.8-129 | 19.6 |
| D90IR-CTV | (%) | – | – | – | 88.0 | 67.8-106.0 | 10.9 |
| (Gy) | – | – | – | 18.3 | 12.6-22.3 | 3 | |
| EQD2αβ10 D90IR-CTV | (Gy) | – | – | – | 70.5 | 59.9-78.3 | 5.2 |
| V100 | (%) | 99.0 | 95.3-100 | 1.2 | 98.6 | 92.3-99.3 | 2.2 |
| V150 | (%) | 52.2 | 28.3-69.4 | 11.2 | 57.2 | 48.5-67.1 | 5.3 |
| V200 | (%) | 16.1 | 11.6-39.6 | 7.5 | 23.9 | 20.5-34.0 | 3.6 |
| Bladder | |||||||
| D0.1ccb | (%) | 100.8 | 84.8-125.1 | 10.2 | 92.8 | 82.3-103.7 | 6 |
| D1ccb | (%) | 88.6 | 72.0-106.5 | 8.8 | 85.0 | 76.7-90.5 | 4.5 |
| D2ccb | (%) | 83.8 | 65.0-100.4 | 9.5 | 79.6 | 71.6-85.0 | 4.5 |
| EQD2αβ3 D2ccb | (Gy) | 76.8 | 66.6-90.9 | 6 | 74.5 | 70.3-78.0 | 2.3 |
| Rectum | |||||||
| D0.1ccr | (%) | 86.5 | 29.6-104.0 | 21.1 | 82.2 | 52.1-90.7 | 11 |
| D1ccr | (%) | 72.6 | 21.3-85.3 | 18.4 | 68.4 | 42.3-79.1 | 10.9 |
| D2ccr | (%) | 65.1 | 19.0-77.8 | 15.1 | 60.7 | 38.1-75.1 | 10.5 |
| EQD2αβ3 D2ccr | (Gy) | 66.4 | 51.9-77.4 | 7.6 | 64.3 | 55.1-72.0 | 4.6 |
| Sigmoid | |||||||
| D0.1ccs | (%) | 78.8 | 61.1-129.6 | 23.9 | 75.2 | 35.1-93.8 | 17.9 |
| D1ccs | (%) | 70.0 | 50.2-106.0 | 17.6 | 56.5 | 29.2-81.5 | 15.6 |
| D2ccs | (%) | 60.9 | 46.0-97.8 | 17.2 | 52.4 | 24.5-73.7 | 14.4 |
| EQD2αβ3 D2ccs | (Gy) | 59.8 | 53.4-81.1 | 8.5 | 60.7 | 50.9-70.3 | 5.7 |
CT – planification based on CT-scan = 16 patients (pts); MRI – planification based on MRI = 17 pts; CTV – clinical target volume; HR-CTV – high-risk CTV; IR-CTV – intermediate-risk CTV; D90CTV – dose delivered to 90% of the CTV; D90HR-CTV – dose delivered to 90% of the HR-CTV; D90IR-CTV – dose delivered to 90% of the IR-CTV; EQD2αβ10 – equivalent dose at 2 Gy per fraction for αβ = 10 (tumor); EQD2αβ3 – equivalent dose at 2 Gy per fraction for αβ = 3 (normal tissues); V100 – volume receiving 100% of the prescribed dose; V150 – volume receiving 150% of the prescribed dose; V200 – volume receiving 200% of the prescribed dose; D0.1ccb – dose delivered to 0.1% of the bladder volume; D0.1ccr – dose delivered to 0.1% of the rectum volume; D0.1ccs – dose delivered to 0.1% of the sigmoid volume; D1ccb – dose delivered to 1% of the bladder volume; D1ccr – dose delivered to 1% of the rectum volume; D1ccs – dose delivered to 1% of the sigmoid volume; D2ccb – dose delivered to 2% of the bladder volume; D2ccr – dose delivered to 2% of the rectum volume; D2ccs – dose delivered to 2% of the sigmoid volume; SD – standard deviation